세계의 유전성 트랜스사이레틴 아밀로이드증 시장 보고서(2025년)

Hereditary Transthyretin Amyloidosis Global Market Report 2025

US $ 4,490 ￦ 6,151,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 8,891,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,632,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 유전성 트랜스사이레틴 아밀로이드증 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 예측기간의 성장은 고령자 인구 증가, 가처분 소득 증가, 유전성 트랜스사이레틴 아밀로이드증의 이환율 상승, 신약 개발의 성장, 유전자 검사의 진보 등의 요인에 의한 것으로 예측됩니다.

노인 인구 증가는 유전성 트랜스 사이레틴 아밀로이드증 시장의 성장을 이끌 것으로 예측됩니다. 이 인구층의 성장은 헬스케어와 생활 수준의 진보에 의한 평균 수명의 성장에 추진되고 있습니다. 유전성 트랜스사이레틴 아밀로이드증(hATTR)은 특히 노인에게 영향을 미치고, 진행성 신경장애와 심근증을 유발하며, 노인의 이환율을 증가시킵니다. 인구문제연구소에 의하면 미국의 65세 이상 인구는 2022년 5,800만명에서 2050년에는 8,200만명으로 47% 증가할 것으로 예측되고 있습니다.

유전성 트랜스사이레틴 아밀로이드증 시장의 각 회사는 트랜스사이레틴(TTR) 단백질의 생산을 억제하는 RNAi 치료제 등 최첨단 치료제를 개발하고 있습니다. 2024년 10월, Alnylam Pharmaceuticals, Inc.는 심근증을 동반한 트랜스사이레틴 아밀로이드증을 치료하기 위한 부트리실란(AMVUTTRA)의 신약 추가 신청을 미국 FDA에 제출했습니다. 부트리실란의 피하 투여는 정맥내 투여를 대체하는 보다 환자에게 친화적인 치료법이며, 이 심각한 질환을 앓고 있는 환자에게 유망한 옵션으로 자리매김합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계 유전성 트랜스사이레틴 아밀로이드증 시장의 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인 및 억제요인)
• 최종 이용 산업의 분석
• 세계의 유전성 트랜스사이레틴 아밀로이드증 시장 : 성장률 분석
• 세계의 유전성 트랜스사이레틴 아밀로이드증 시장 실적: 규모와 성장, 2019-2024년
• 세계의 유전성 트랜스사이레틴 아밀로이드증 시장 예측 : 규모와 성장, 2024-2029년, 2034년
• 세계의 유전성 트랜스사이레틴 아밀로이드증 전체 시장 규모(TAM)

제6장 시장 세분화

• 세계의 유전성 트랜스사이레틴 아밀로이드증 시장 : 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 경구
• 피하 주사
• 기타
• 세계의 유전성 트랜스사이레틴 아밀로이드증 시장 : 약제 클래스별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• RNAi제(파티실란)
• 저분자 간섭 RNA(siRNA)(부트리실란)
• 세계의 유전성 트랜스사이레틴 아밀로이드증 시장 : 유통 채널별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 병원 약국
• 소매 약국
• 세계의 유전성 트랜스사이레틴 아밀로이드증 시장 : 용도별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 병원
• 클리닉
• 기타
• 세계의 유전성 트랜스사이레틴 아밀로이드증 시장 : 경구별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 타파미디스
• 지플루니살
• 실험적 경구요법
• 세계의 유전성 트랜스사이레틴 아밀로이드증 시장 : 피하 주사별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 파티실란
• 이노테르센
• 브트리실란
• 세계의 유전성 트랜스사이레틴 아밀로이드증 시장 : 기타 세분화별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 정맥내 요법
• 유전자 침묵 요법
• CRISPR 기반 치료법

제7장 지역별/국가별 분석

• 세계의 유전성 트랜스사이레틴 아밀로이드증 시장 :지역별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 세계의 유전성 트랜스사이레틴 아밀로이드증 시장 : 국가별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• 유전성 트랜스사이레틴 아밀로이드증 시장 : 경쟁 구도
• 유전성 트랜스사이레틴 아밀로이드증 시장 : 기업 프로파일
  • Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
  • AbbVie Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Sanofi SA : 개요, 제품 및 서비스, 전략 및 재무 분석
  • AstraZeneca plc : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Novo Nordisk : 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• Regeneron Pharmaceuticals Inc.
• Alexion Pharmaceuticals Inc.
• Alnylam Pharmaceuticals Inc.
• PTC Therapeutics Inc.
• Ionis Pharmaceuticals Inc.
• BridgeBio Pharma Inc.
• Akcea Therapeutics
• Prothena Corporation plc
• Intellia Therapeutics Inc.
• YoITech Therapeutics
• Corino Therapeutics Inc.
• Attralus Inc.
• BSIM Therapeutics SA
• Eidos Therapeutics
• Autotac Bio Inc

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

• 유전성 트랜스사이레틴 아밀로이드증 시장(2029년) : 새로운 기회를 제공하는 국가
• 유전성 트랜스사이레틴 아밀로이드증 시장(2029년) : 새로운 기회를 제공하는 부문
• 유전성 트랜스사이레틴 아밀로이드증 시장(2029년) : 성장 전략
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제36장 부록

JHS

영문 목차

영문목차

Hereditary transthyretin amyloidosis (hATTR) is a rare, inherited disorder caused by mutations in the TTR gene, leading to the misfolding and accumulation of transthyretin protein as amyloid deposits in various organs. This condition primarily impacts the nervous system, heart, and other tissues, resulting in progressive neuropathy and cardiomyopathy.

The main treatment types for hereditary transthyretin amyloidosis include oral administration, subcutaneous injection, and other methods. Oral treatments, such as tablets, capsules, or liquids, provide a convenient and patient-friendly option, improving accessibility and adherence. The drug classes used in treating hATTR amyloidosis include RNAi agents such as patisiran and small interfering RNAs (siRNAs) such as vutrisiran. These therapies are distributed through hospital pharmacies and retail pharmacies and are used in settings such as hospitals, clinics, and other healthcare facilities.

The hereditary transthyretin amyloidosis market research report is one of a series of new reports from The Business Research Company that provides hereditary transthyretin amyloidosis market statistics, including the hereditary transthyretin amyloidosis industry global market size, regional shares, competitors with the hereditary transthyretin amyloidosis market share, detailed hereditary transthyretin amyloidosis market segments, market trends, and opportunities, and any further data you may need to thrive in the hereditary transthyretin amyloidosis industry. This hereditary transthyretin amyloidosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hereditary transthyretin amyloidosis market size has grown strongly in recent years. It will grow from $1.36 billion in 2024 to $1.50 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. The growth during the historic period can be attributed to factors such as the rising incidence of hereditary transthyretin amyloidosis, increased research and development activities, a growing number of cardiac amyloidosis cases, heightened disease awareness, and improvements in healthcare infrastructure.

The hereditary transthyretin amyloidosis market size is expected to see strong growth in the next few years. It will grow to $2.14 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. The growth during the forecast period can be attributed to factors such as the increasing geriatric population, rising disposable incomes, a higher incidence of hereditary transthyretin amyloidosis, growth in the development of new drugs, and advancements in genetic testing. Key trends in the forecast period include the development of advanced treatment products, improvements in diagnostic techniques, progress in drug development, rising demand for effective therapies, and advancements in medical technology.

The increasing geriatric population is expected to drive the growth of the hereditary transthyretin amyloidosis market. This population, defined as individuals aged 65 and older, often requires specialized healthcare due to the aging process. The growth in this demographic is fueled by rising life expectancy, thanks to advancements in healthcare and living standards. Hereditary transthyretin amyloidosis (hATTR) particularly affects the elderly, causing progressive neuropathy and cardiomyopathy, which increases morbidity in older individuals. According to the Population Reference Bureau, the U.S. population aged 65 and older is projected to rise from 58 million in 2022 to 82 million by 2050, representing a 47% increase. This growing geriatric population is contributing to the market's expansion.

Companies in the hereditary transthyretin amyloidosis market are developing cutting-edge therapeutics such as RNAi therapeutics to reduce the production of the transthyretin (TTR) protein. RNAi therapeutics use RNA interference technology to silence specific genes and reduce the production of proteins that cause diseases. For example, in October 2024, Alnylam Pharmaceuticals, Inc. submitted a supplemental new drug application (sNDA) to the U.S. FDA for Vutrisiran (AMVUTTRA) to treat transthyretin amyloidosis with cardiomyopathy. This RNAi therapy targets the TTR protein, a key player in the disease's progression. Vutrisiran's subcutaneous administration offers a more patient-friendly alternative to intravenous treatments, positioning it as a promising option for those affected by this severe condition.

In July 2023, Ionis Pharmaceuticals, Inc. entered into a partnership with AstraZeneca plc to co-develop and market eplontersen for treating transthyretin amyloidosis (ATTR) in the U.S. This collaboration also aims to enhance global access to the therapy by leveraging AstraZeneca's broad commercial presence, particularly in Latin America and other international regions. AstraZeneca is a UK-based biopharmaceutical company specializing in the discovery, development, and commercialization of prescription medicines.

Major players in the hereditary transthyretin amyloidosis market are Pfizer Inc., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Novo Nordisk, Regeneron Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., BridgeBio Pharma Inc., Akcea Therapeutics, Prothena Corporation plc, Intellia Therapeutics Inc., YoITech Therapeutics, Corino Therapeutics Inc., Attralus Inc., BSIM Therapeutics SA, Eidos Therapeutics, and Autotac Bio Inc.

North America was the largest region in the hereditary transthyretin amyloidosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hereditary transthyretin amyloidosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hereditary transthyretin amyloidosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hereditary transthyretin amyloidosis market consists of revenues earned by entities by providing services such as diagnostic services, treatment services, and genetic counseling services. The market value includes the value of related goods sold by the service provider or included within the service offering. The hereditary transthyretin amyloidosis market also includes sales of genetic testing kits, imaging technologies, biomarkers, and assays. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hereditary Transthyretin Amyloidosis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hereditary transthyretin amyloidosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hereditary transthyretin amyloidosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hereditary transthyretin amyloidosis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Oral; Subcutaneous Injection; Other Types
• 2) By Drug Class: RNAi Agents (Patisiran); Small Interfering RNAs (siRNAs) (Vutrisiran)
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies
• 4) By Application: Hospital; Clinic; Other Applications
• Subsegments:
• 1) By Oral: Tafamidis; Diflunisal; Experimental Oral Therapies
• 2) By Subcutaneous Injection: Patisiran; Inotersen; Vutrisiran
• 3) By Other Types: Intravenous Therapies; Gene Silencing Therapies; CRISPR-Based Therapies
• Companies Mentioned: Pfizer Inc.; AbbVie Inc.; Sanofi S.A.; AstraZeneca plc; Novo Nordisk
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hereditary Transthyretin Amyloidosis Market Characteristics

3. Hereditary Transthyretin Amyloidosis Market Trends And Strategies

4. Hereditary Transthyretin Amyloidosis Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Hereditary Transthyretin Amyloidosis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Hereditary Transthyretin Amyloidosis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Hereditary Transthyretin Amyloidosis Market Growth Rate Analysis
• 5.4. Global Hereditary Transthyretin Amyloidosis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Hereditary Transthyretin Amyloidosis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Hereditary Transthyretin Amyloidosis Total Addressable Market (TAM)

6. Hereditary Transthyretin Amyloidosis Market Segmentation

• 6.1. Global Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Subcutaneous Injection
• Other Types
• 6.2. Global Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• RNAi Agents (Patisiran)
• Small Interfering RNAs (siRNAs) (Vutrisiran)
• 6.3. Global Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• 6.4. Global Hereditary Transthyretin Amyloidosis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Clinic
• Other Applications
• 6.5. Global Hereditary Transthyretin Amyloidosis Market, Sub-Segmentation Of Oral, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tafamidis
• Diflunisal
• Experimental Oral Therapies
• 6.6. Global Hereditary Transthyretin Amyloidosis Market, Sub-Segmentation Of Subcutaneous Injection, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Patisiran
• Inotersen
• Vutrisiran
• 6.7. Global Hereditary Transthyretin Amyloidosis Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous Therapies
• Gene Silencing Therapies
• CRISPR-Based Therapies

7. Hereditary Transthyretin Amyloidosis Market Regional And Country Analysis

• 7.1. Global Hereditary Transthyretin Amyloidosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Hereditary Transthyretin Amyloidosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hereditary Transthyretin Amyloidosis Market

• 8.1. Asia-Pacific Hereditary Transthyretin Amyloidosis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hereditary Transthyretin Amyloidosis Market

• 9.1. China Hereditary Transthyretin Amyloidosis Market Overview
• 9.2. China Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hereditary Transthyretin Amyloidosis Market

• 10.1. India Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hereditary Transthyretin Amyloidosis Market

• 11.1. Japan Hereditary Transthyretin Amyloidosis Market Overview
• 11.2. Japan Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hereditary Transthyretin Amyloidosis Market

• 12.1. Australia Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hereditary Transthyretin Amyloidosis Market

• 13.1. Indonesia Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hereditary Transthyretin Amyloidosis Market

• 14.1. South Korea Hereditary Transthyretin Amyloidosis Market Overview
• 14.2. South Korea Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hereditary Transthyretin Amyloidosis Market

• 15.1. Western Europe Hereditary Transthyretin Amyloidosis Market Overview
• 15.2. Western Europe Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hereditary Transthyretin Amyloidosis Market

• 16.1. UK Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hereditary Transthyretin Amyloidosis Market

• 17.1. Germany Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hereditary Transthyretin Amyloidosis Market

• 18.1. France Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hereditary Transthyretin Amyloidosis Market

• 19.1. Italy Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hereditary Transthyretin Amyloidosis Market

• 20.1. Spain Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hereditary Transthyretin Amyloidosis Market

• 21.1. Eastern Europe Hereditary Transthyretin Amyloidosis Market Overview
• 21.2. Eastern Europe Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hereditary Transthyretin Amyloidosis Market

• 22.1. Russia Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hereditary Transthyretin Amyloidosis Market

• 23.1. North America Hereditary Transthyretin Amyloidosis Market Overview
• 23.2. North America Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hereditary Transthyretin Amyloidosis Market

• 24.1. USA Hereditary Transthyretin Amyloidosis Market Overview
• 24.2. USA Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hereditary Transthyretin Amyloidosis Market

• 25.1. Canada Hereditary Transthyretin Amyloidosis Market Overview
• 25.2. Canada Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hereditary Transthyretin Amyloidosis Market

• 26.1. South America Hereditary Transthyretin Amyloidosis Market Overview
• 26.2. South America Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hereditary Transthyretin Amyloidosis Market

• 27.1. Brazil Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hereditary Transthyretin Amyloidosis Market

• 28.1. Middle East Hereditary Transthyretin Amyloidosis Market Overview
• 28.2. Middle East Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hereditary Transthyretin Amyloidosis Market

• 29.1. Africa Hereditary Transthyretin Amyloidosis Market Overview
• 29.2. Africa Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hereditary Transthyretin Amyloidosis Market Competitive Landscape And Company Profiles

• 30.1. Hereditary Transthyretin Amyloidosis Market Competitive Landscape
• 30.2. Hereditary Transthyretin Amyloidosis Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novo Nordisk Overview, Products and Services, Strategy and Financial Analysis

31. Hereditary Transthyretin Amyloidosis Market Other Major And Innovative Companies

• 31.1. Regeneron Pharmaceuticals Inc.
• 31.2. Alexion Pharmaceuticals Inc.
• 31.3. Alnylam Pharmaceuticals Inc.
• 31.4. PTC Therapeutics Inc.
• 31.5. Ionis Pharmaceuticals Inc.
• 31.6. BridgeBio Pharma Inc.
• 31.7. Akcea Therapeutics
• 31.8. Prothena Corporation plc
• 31.9. Intellia Therapeutics Inc.
• 31.10. YoITech Therapeutics
• 31.11. Corino Therapeutics Inc.
• 31.12. Attralus Inc.
• 31.13. BSIM Therapeutics SA
• 31.14. Eidos Therapeutics
• 31.15. Autotac Bio Inc

32. Global Hereditary Transthyretin Amyloidosis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hereditary Transthyretin Amyloidosis Market

34. Recent Developments In The Hereditary Transthyretin Amyloidosis Market

35. Hereditary Transthyretin Amyloidosis Market High Potential Countries, Segments and Strategies

• 35.1 Hereditary Transthyretin Amyloidosis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Hereditary Transthyretin Amyloidosis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Hereditary Transthyretin Amyloidosis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료